Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Update

Posted by Alphonse Anthony on Mar 4th, 2025

Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Free Report) was the recipient of a large decrease in short interest in February. As of February 15th, there was short interest totalling 57,500 shares, a decrease of 31.1% from the January 31st total of 83,500 shares. Approximately 2.1% of the shares of the company are sold short. Based on an average daily volume of 636,200 shares, the short-interest ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, Aegis reiterated a “buy” rating and set a $15.00 target price on shares of Sunshine Biopharma in a research report on Thursday, December 5th.

Get Our Latest Stock Analysis on SBFM

Institutional Trading of Sunshine Biopharma

An institutional investor recently bought a new position in Sunshine Biopharma stock. Connective Capital Management LLC acquired a new stake in Sunshine Biopharma, Inc. (NASDAQ:SBFM – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,345 shares of the company’s stock, valued at approximately $34,000. Connective Capital Management LLC owned approximately 0.93% of Sunshine Biopharma as of its most recent SEC filing. Hedge funds and other institutional investors own 41.98% of the company’s stock.

Sunshine Biopharma Price Performance

Shares of NASDAQ:SBFM traded down $0.16 during mid-day trading on Tuesday, reaching $2.15. 50,994 shares of the company traded hands, compared to its average volume of 279,006. Sunshine Biopharma has a 52 week low of $2.05 and a 52 week high of $285.00. The firm has a market cap of $2.63 million, a PE ratio of -0.01 and a beta of 1.33. The company’s 50 day moving average price is $2.76 and its 200-day moving average price is $2.83.

Sunshine Biopharma Company Profile

(Get Free Report)

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.